Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 4/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.34 |
| ▸ | CIT | O14578 | 2/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.34 |
| ▸ | STK10 | O94804 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488708 | 0.82 | PTGS2 (0.44) | PTGIR | |
| SCHEMBL3885071 | 0.75 | KMT2A (0.44) | KMT2AMEN1PTGIRAURKAAURKB | |
| SCHEMBL3889385 | 0.75 | KDM4E (0.40) | MAPK1KDM4EATMCYP1A2CYP2D6 | |
| SCHEMBL11484651 | 0.73 | PTGIR (0.66) | KMT2AMEN1PTGIRAURKAAURKB | |
| SCHEMBL4695684 | 0.72 | CYP1A2 (0.37) | KMT2AMAPK1KDM4EATMCYP1A2 | |
| SCHEMBL4502812 | 0.72 | NPC1 (0.33) | KMT2AMEN1MAPK1KDM4EATM | |
| SCHEMBL3882223 | 0.71 | PTGIR (0.38) | KMT2AMEN1PTGIRMAPK1KDM4E | |
| SCHEMBL11002490 | 0.69 | P2RX4 (0.38) | KMT2AMEN1KDM4EATM | |
| SCHEMBL14235673 | 0.68 | MEN1 (0.53) | KMT2AMEN1PTGIRMAPK1BRAF | |
| SCHEMBL14519366 | 0.68 | PTGIR (0.58) | KMT2AMEN1PTGIRAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550498-B2 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-06-23 | — | — | US | claimed |
| EP-1686989-B1 | USE OF 1,2-DIAZA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-01-14 | — | — | EP | claimed |
| EP-1587807-B1 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2008-06-18 | — | — | EP | claimed |
| US-20070173492-A1 | 1,2-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-07-26 | — | — | US | claimed |
| EP-1686989-A1 | USE OF 1,2-DIAZA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | Pliva - Istrazivacki Institut d.o.o. (HR) | 2006-08-09 | — | — | EP | claimed |
| EP-1587807-A3 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | Pliva-Istrazivacki Institut D.D.O. (HR) | 2005-11-16 | — | — | EP | claimed |
| EP-1587807-A2 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | Pliva-Istrazivacki Institut D.D.O. (HR) | 2005-10-26 | — | — | EP | claimed |
| US-20050209296-A1 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | claimed |
| WO-2005049015-A1 | USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-02 | — | — | WO | claimed |
| WO-2003099822-A2 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-12-04 | — | — | WO | claimed |
| US-7550498-B2 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-06-23 | — | — | US | disclosed |
| EP-1686989-B1 | USE OF 1,2-DIAZA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-01-14 | — | — | EP | disclosed |
| EP-1587807-B1 | 1,2-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2008-06-18 | — | — | EP | disclosed |
| US-20070173492-A1 | 1,2-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-07-26 | — | — | US | disclosed |
| EP-1686989-A1 | USE OF 1,2-DIAZA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | Pliva - Istrazivacki Institut d.o.o. (HR) | 2006-08-09 | — | — | EP | disclosed |
| US-20050209296-A1 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | disclosed |
| WO-2005049015-A1 | USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209296-A1 | 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | KMT2A 3889/4885MEN1 890/4885PTGIR 1190/4885 |
| US-20070173492-A1 | 1,2-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, DDT, BCHE | KMT2A 2062/4885MEN1 283/4885PTGIR 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.